Title: AstraZeneca,
LegoChem Biosciences To Co-Develop Novel Antibiotics Publication: Firstword Pharma Date: 23 Dec 2012 URL: link
to website
Summary
·
AstraZeneca licensed an antibiotic
drug candidate from South Korea's LegoChem Biosciences to treat drug-resistant
bacterial infections, reported Asian Scientist. ·
The companies will investigate
whether the combination of a cephalosporin with AstraZeneca's preclinical beta
lactamase inhibitor (BLI) can break down Gram-negative bacteria's resistance to
the treatment. About LegoChem Biosciences LegoChem Biosciences, Inc. (LCB) is a
research-based biotechnology company dedicated to discovering, developing, and
commercializing innovative medicines by leveraging our chemistry expertise to
make conventional biologics targeted and more potent for the benefit of
patients with diseases of high unmet medical needs. We are advancing
sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants,
oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).
|
|
IP : 106.243.208.*** 
|
